{"id":28,"date":"2008-07-11T20:25:48","date_gmt":"2008-07-12T01:25:48","guid":{"rendered":"http:\/\/blogs.nejm.org\/pov\/hiv-id-observations\/index.php\/2008\/07\/11\/m184v-so-many-options-but-does-that-include-tdfftcefv\/"},"modified":"2008-07-11T20:25:48","modified_gmt":"2008-07-12T01:25:48","slug":"m184v-so-many-options-but-does-that-include-tdfftcefv","status":"publish","type":"post","link":"https:\/\/blogs.nejm.org\/hiv-id-observations\/index.php\/m184v-so-many-options-but-does-that-include-tdfftcefv\/2008\/07\/11\/","title":{"rendered":"M184V: So many options, but does that include TDF\/FTC\/EFV?"},"content":{"rendered":"

Co-formulated TDF\/FTC\/EFV (Atripla)\u00a0is a nifty bit of pharmacologic packaging (ever so much more so since it involves collaboration between two different pharmaceutical companies, ahem) —\u00a0and our patients have noticed.\u00a0 All of us who practice HIV medicine have been asked for the “one pill” treatment; often these requests make sense, sometimes they don’t.<\/p>\n

It’s easy to say when it’s a bad idea (known NNRTI resistance, for example), but\u00a0sometimes it’s not so clear.<\/p>\n

We presented a case in AIDS Clinical Care<\/em><\/a> of someone with documented M184V several years previously (before a treatment interruption) who now needed to go back on treatment.\u00a0 Her request:\u00a0 the “one pill” treatment.\u00a0 One of our clinical experts (Joel Gallant) said he wouldn’t do it; the other (Jose Arribas) said he would.\u00a0 Not surprisingly, there were good reasons provided by both for their decisions.<\/p>\n

We also asked if they’d order a viral tropism test.\u00a0 Joel — no.\u00a0 Jose — yes.<\/p>\n

Thoughts?\u00a0 What do you do for patients who only have M184V?<\/p>\n","protected":false},"excerpt":{"rendered":"

Co-formulated TDF\/FTC\/EFV (Atripla)\u00a0is a nifty bit of pharmacologic packaging (ever so much more so since it involves collaboration between two different pharmaceutical companies, ahem) —\u00a0and our patients have noticed.\u00a0 All of us who practice HIV medicine have been asked for the “one pill” treatment; often these requests make sense, sometimes they don’t. It’s easy to […]<\/p>\n","protected":false},"author":6,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2,4,5,8],"tags":[89,580,903],"class_list":["post-28","post","type-post","status-publish","format-standard","hentry","category-antiretroviral-rounds","category-hiv","category-infectious-diseases","category-patient-care","tag-atripla","tag-m184v","tag-tdfftcefv"],"post_mailing_queue_ids":[],"_links":{"self":[{"href":"https:\/\/blogs.nejm.org\/hiv-id-observations\/index.php\/wp-json\/wp\/v2\/posts\/28","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.nejm.org\/hiv-id-observations\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.nejm.org\/hiv-id-observations\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.nejm.org\/hiv-id-observations\/index.php\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.nejm.org\/hiv-id-observations\/index.php\/wp-json\/wp\/v2\/comments?post=28"}],"version-history":[{"count":0,"href":"https:\/\/blogs.nejm.org\/hiv-id-observations\/index.php\/wp-json\/wp\/v2\/posts\/28\/revisions"}],"wp:attachment":[{"href":"https:\/\/blogs.nejm.org\/hiv-id-observations\/index.php\/wp-json\/wp\/v2\/media?parent=28"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.nejm.org\/hiv-id-observations\/index.php\/wp-json\/wp\/v2\/categories?post=28"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.nejm.org\/hiv-id-observations\/index.php\/wp-json\/wp\/v2\/tags?post=28"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}